Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

Explore how neutrophils shape the immune response in health and disease. This poster highlights neutrophil pathogen defense mechanisms, including phagocytosis, degranulation, and NETosis, as well as neutrophil roles in inflammation and NET-associated pathologies.
DOWNLOAD NOWHepcidin-25 is a peptide hormone that regulates iron homeostasis and has antibacterial activity.1 It is predominantly synthesized by hepatocytes and secreted into the circulation. Hepcidin-25 binds to ferroportin, a membrane-bound iron exporter expressed by macrophages, enterocytes, and hepatocytes, inducing ferroportin internalization and degradation, which increases intracellular iron levels and decreases dietary iron absorption and plasma iron levels. It is bactericidal against multidrug-resistant clinical isolates of Gram-negative and Gram-positive bacteria, including P. aeruginosa, E. coli, K. pneumoniae, S. aureus, S. epidermidis, and E. faecium, when used at concentrations ranging from 6.25 to 50 µg/ml.2 Serum hepcidin-25 levels are increased in patients with chronic kidney disease (CKD).3
WARNING This product is not for human or veterinary use.
1. Hepcidin in human iron disorders: Diagnostic implications. Clin. Chem. 57(12), 1650-1669 (2011).
2. Antimicrobial activity of human hepcidin 20 and 25 against clinically relevant bacterial strains: Effect of copper and acidic pH. Peptides 31(11), 1995-2002 (2010).
3. Hepcidin is a potential regulator of iron status in chronic kidney disease. Ther. Apher. Dial. 17(1), 1-8 (2013).